Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies due to the absence of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression [1]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.